EPO: The Peptide Hormone That Defined Endurance Doping
Peptides and Athletic Performance
165 Amino Acids
Erythropoietin is a 165-amino-acid glycoprotein hormone that controls red blood cell production, saved millions of kidney disease patients from chronic transfusion dependence, and became the most infamous doping agent in endurance sports history.
Jelkmann, Physiological Reviews, 2011
Jelkmann, Physiological Reviews, 2011
View as imageFew molecules in biomedical history have occupied as many contradictory roles as erythropoietin. EPO is a life-saving drug for patients with chronic kidney disease, a molecule whose oxygen-sensing regulation earned the 2019 Nobel Prize in Physiology or Medicine, and the substance that fueled the most systematic doping program professional cycling has ever seen. It is a 165-amino-acid glycoprotein produced primarily by the kidneys, and its story spans fundamental biology, pharmaceutical innovation, sporting fraud, and emerging neuroscience.
This article covers EPO from molecular biology through clinical application, the doping era, detection science, and the expanding research into EPO's non-hematopoietic functions. For related coverage of other peptides in athletic performance contexts, see the cluster articles on AICAR and endurance enhancement, MOTS-c as an exercise mimetic, and how GLP-1 agonists affect exercise capacity.
Key Takeaways
- EPO is a 165-amino-acid, 34 kDa glycoprotein hormone produced mainly by kidney peritubular cells in response to low oxygen levels (hypoxia)
- Recombinant human EPO (epoetin alfa/Epogen) was FDA-approved in 1989 for anemia in chronic kidney disease; by 2005, 99% of US hemodialysis patients received ESA therapy
- The 2019 Nobel Prize in Physiology or Medicine was awarded to Semenza, Ratcliffe, and Kaelin for discovering the HIF oxygen-sensing pathway that controls EPO production
- EPO became cycling's dominant doping agent in the 1990s; Lance Armstrong was stripped of 7 Tour de France titles in 2012 after USADA found systematic EPO use dating to 1996
- The first reliable urine detection test for recombinant EPO (isoelectric focusing) was introduced in 2000, a full decade after the IOC banned its use in 1990
- Beyond blood cell production, EPO shows neuroprotective, cardioprotective, and anti-apoptotic properties through non-canonical receptors in brain, heart, and other tissues
What Is Erythropoietin?
Erythropoietin is a glycoprotein hormone consisting of 165 amino acids arranged in four antiparallel alpha-helices connected by two beta-sheets, stabilized by two internal disulfide bridges (Cys7-Cys161 and Cys29-Cys33). The protein is heavily glycosylated, with carbohydrate chains accounting for approximately 40% of its total molecular weight of 30.4-34 kDa. Four glycosylation sites (three N-linked, one O-linked) are critical for the protein's biological activity and circulating half-life; removal of glycan chains reduces EPO's in vivo potency dramatically while preserving in vitro receptor binding.
EPO is produced primarily by peritubular interstitial fibroblast-like cells in the kidney cortex and outer medulla. The liver contributes a smaller fraction (approximately 10-15% in adults, but the dominant source in fetal development). Production is regulated by oxygen availability: when tissue oxygen drops, hypoxia-inducible factor-2 alpha (HIF-2alpha) is stabilized, dimerizes with HIF-1beta, and translocates to the nucleus where it activates EPO gene transcription. Under normal oxygen conditions, prolyl hydroxylase domain enzymes (PHDs) tag HIF-2alpha for degradation via the von Hippel-Lindau (VHL) protein ubiquitin ligase complex. This oxygen-sensing mechanism earned William Kaelin Jr., Sir Peter Ratcliffe, and Gregg Semenza the 2019 Nobel Prize in Physiology or Medicine.
Once secreted, EPO circulates to the bone marrow where it binds the erythropoietin receptor (EPOR) on erythroid progenitor cells, activating JAK2/STAT5 signaling cascades that promote survival, proliferation, and differentiation into mature red blood cells. Without EPO signaling, erythroid progenitors undergo apoptosis; EPO's primary function is anti-apoptotic rescue of committed red cell precursors rather than proliferative stimulation. A healthy adult produces enough EPO to generate approximately 2 million new red blood cells per second, maintaining hemoglobin levels between 12-17 g/dL. EPO levels can increase 100-fold or more during severe hypoxia or hemorrhage, demonstrating the enormous dynamic range of this regulatory system.
From Discovery to Drug: EPO's Medical Revolution
The existence of a humoral factor controlling red blood cell production was hypothesized as early as 1906 by Paul Carnot, who called it "hemopoietine." Decades of work followed, with Erslev demonstrating in 1953 that plasma from anemic rabbits could stimulate red cell production in normal rabbits, and Jacobson showing in 1957 that the kidney was the primary production site. But the factor was not purified until 1977, when Goldwasser and Kung isolated EPO from 2,550 liters of human urine collected from patients with aplastic anemia, yielding just milligrams of pure protein. This heroic biochemistry enabled amino acid sequencing, which in turn allowed the human EPO gene to be cloned independently by two groups in 1985 (Lin et al. at Amgen and Jacobs et al. at Genetics Institute), enabling production of recombinant human EPO in Chinese hamster ovary (CHO) cells.
Amgen's epoetin alfa (Epogen) received FDA approval in June 1989 for treatment of anemia associated with chronic kidney disease (CKD). The approval transformed nephrology. Before recombinant EPO, CKD patients with severe anemia required regular blood transfusions, carrying risks of iron overload, transfusion reactions, and blood-borne infections. Within a decade, transfusion rates in dialysis patients dropped precipitously. By 2005, 99% of US in-center hemodialysis patients received erythropoiesis-stimulating agent (ESA) therapy.
Subsequent approvals expanded EPO's indications to chemotherapy-induced anemia in cancer patients, surgical blood loss reduction, and anemia associated with HIV/zidovudine treatment. Darbepoetin alfa (Aranesp), a longer-acting EPO analog with additional glycosylation sites, was approved in 2001. At its peak, ESAs generated over $10 billion annually in global pharmaceutical revenue, making EPO one of the most commercially successful biotechnology products in history.
The Safety Reckoning: When Higher Isn't Better
EPO's clinical story took a sharp turn with safety data from large randomized trials in the mid-2000s. Three landmark studies changed practice:
The CHOIR trial (2006) randomized 1,432 CKD patients to target hemoglobin of 13.5 g/dL versus 11.3 g/dL. The higher-target group had significantly more cardiovascular events (death, myocardial infarction, heart failure, stroke) without improvement in quality of life.
The CREATE trial (2006) found that early, full correction of anemia with epoetin beta did not reduce cardiovascular events compared to partial correction, and the higher-hemoglobin group had more dialysis initiation.
The TREAT trial (2009) in diabetic CKD patients showed that darbepoetin alfa targeting hemoglobin of 13 g/dL nearly doubled the risk of stroke compared to placebo, with no reduction in cardiovascular events or death.
These findings led the FDA to add black box warnings to all ESA products in 2007 and again in 2011, mandating that ESAs target the lowest hemoglobin level sufficient to avoid transfusion (generally 10-12 g/dL). The mechanism behind the cardiovascular risk remains debated: direct vascular effects of EPO, increased blood viscosity from excessive red cell mass, and off-target receptor activation on vascular endothelial and smooth muscle cells have all been proposed. The same physiology that made EPO attractive for doping (more red cells, more oxygen delivery) proved dangerous when pushed beyond physiological limits.
EPO and Endurance Doping: The Dark Chapter
Recombinant EPO entered the doping world almost immediately after its clinical approval. The logic was straightforward: more red blood cells mean higher oxygen-carrying capacity, which translates to improved aerobic endurance. A 7-10% increase in hemoglobin concentration can improve VO2max (maximal oxygen uptake) by a similar magnitude, a difference that separates winners from mid-pack finishers in endurance sports.
The early era (late 1980s-1998). EPO use in professional cycling reportedly began in the late 1980s. The IOC banned EPO in 1990, but there was no test to detect it. Recombinant EPO and endogenous EPO are nearly identical proteins; the only structural difference lies in the glycosylation pattern of the carbohydrate chains. For a full decade after the ban, athletes could use EPO with impunity. During this period, suspicious clustering of cardiac deaths among young European professional cyclists raised concerns about EPO-induced polycythemia (dangerously elevated red cell counts) causing blood clotting, stroke, and cardiac arrest during sleep when heart rate drops and viscous blood thickens further.
The Festina affair (1998). The 1998 Tour de France became a watershed when French customs officers discovered hundreds of doses of EPO, growth hormone, and testosterone in the car of Willy Voet, soigneur for the Festina cycling team. The entire Festina team was expelled from the race, multiple other teams withdrew under police pressure, and French law enforcement conducted raids on team hotels and vehicles. Team directors and doctors were arrested. The scandal exposed EPO doping as systemic rather than individual: it was organized at the team level, managed by medical staff, and funded through team budgets. The "Tour of Shame," as it became known, forced cycling's governing body (UCI) to accelerate development of EPO detection methods and fundamentally changed the public perception of professional cycling.
Lance Armstrong and USADA (1996-2012). The US Postal Service cycling team operated what USADA later called "the most sophisticated, professionalized and successful doping program that sport has ever seen." Lance Armstrong, who won seven consecutive Tour de France titles from 1999 to 2005, used EPO, testosterone, cortisone, and blood transfusions dating back to at least 1996. In August 2012, USADA stripped all his competitive results from August 1998 onward, including all seven Tour titles, and imposed a lifetime ban. Armstrong confirmed his EPO use in a January 2013 television interview with Oprah Winfrey, ending years of vehement public denials and legal threats against accusers. The case reshaped anti-doping policy globally: USADA's investigation relied heavily on testimony from former teammates (11 of whom provided evidence), biological passport data, and financial records rather than positive drug tests alone, establishing a precedent for non-analytical findings in doping cases.
The efficacy question. A provocative 2013 analysis in the British Journal of Pharmacology argued that evidence for EPO's performance-enhancing effect in already-trained cyclists is weaker than commonly assumed. The review noted that most studies showing VO2max improvements were conducted in untrained subjects, and that the leap to elite performance enhancement was based more on assumption than controlled trial data. Whether EPO provides a 3%, 5%, or 10% advantage in trained athletes remains genuinely uncertain, though the circumstantial evidence from the doping era strongly suggests a meaningful competitive edge. The widespread and systematic nature of EPO use across multiple teams and sports during the 1990s and 2000s, combined with athletes' willingness to risk career-ending sanctions, argues that the performance benefit was perceived as substantial by those closest to elite competition.
Detection Science: A Decade Behind the Cheaters
The story of EPO detection illustrates the asymmetry between doping innovation and anti-doping response.
Isoelectric focusing (2000). The breakthrough came from French scientist Francoise Lasne, who demonstrated that recombinant EPO and endogenous EPO could be distinguished by their isoelectric focusing (IEF) patterns. Recombinant EPO produced in Chinese hamster ovary (CHO) cells has a different glycosylation profile than human-produced EPO, creating distinct charge patterns on IEF gels followed by immunoblotting. This test was first used at the 2000 Sydney Olympics. However, the detection window is narrow: sensitivity peaks 2-6 days after dosing and drops rapidly outside this window, achieving only about 59% sensitivity overall.
The Athlete Biological Passport (2008). WADA introduced the ABP, which tracks individual athletes' hematological parameters (hemoglobin, reticulocyte percentage, OFF-score) over time. Abnormal fluctuations consistent with EPO use or blood transfusion can trigger sanctions even without a positive direct test. The ABP was a conceptual shift from catching the drug to catching its effects.
Current methods. Modern anti-doping laboratories use a combination of IEF, SAR-PAGE (SDS-PAGE after sialidase treatment), and mass spectrometry-based approaches. Newer biosimilar EPO products with slightly different glycosylation profiles have created additional detection challenges, as the IEF patterns must be updated for each new product entering the market. The emergence of pegylated EPO analogs like pegmolesatide (a synthetic peptide-based ESA approved in China) has added further complexity. These novel EPO mimetics may not be detected by traditional IEF methods designed for first-generation recombinant EPO products.
The cat-and-mouse dynamic between doping chemists and detection scientists continues. Each new EPO formulation or analog requires development of new reference standards, validated detection protocols, and updated testing criteria. WADA-accredited laboratories must continuously adapt their methods to keep pace with pharmaceutical innovation that was designed for legitimate medical use but finds a secondary market in performance enhancement.
Beyond Blood: EPO's Non-Hematopoietic Biology
The most scientifically interesting EPO research of the past two decades concerns functions unrelated to red blood cell production. EPO receptors are expressed in brain, heart, kidney, retina, pancreas, and other non-hematopoietic tissues, where EPO acts through a non-canonical receptor complex (EPOR/betacR, also called EPOR/CD131) distinct from the classical homodimeric EPOR in bone marrow.
Neuroprotection. EPO reduces neuronal apoptosis, oxidative stress, and inflammation in animal models of stroke, traumatic brain injury, and spinal cord injury. The mechanisms include activation of anti-apoptotic pathways (PI3K/Akt, Bcl-xL), suppression of pro-inflammatory cytokines, and promotion of neurogenesis and angiogenesis in damaged brain tissue. A non-hematopoietic EPO splice variant lacking exon 3 has been identified in the human brain, upregulated in ischemic and inflammatory neurological conditions, suggesting endogenous neuroprotective EPO production.
Cardioprotection. EPO preconditioning reduces infarct size by up to 50% in animal models of myocardial ischemia-reperfusion injury. The proposed mechanisms parallel the neuroprotective pathways: anti-apoptotic signaling via PI3K/Akt, reduced oxidative damage, improved microvascular function, and mobilization of endothelial progenitor cells. Small clinical studies of EPO in acute myocardial infarction patients have shown mixed results, with some suggesting reduced infarct size but others showing no benefit or increased adverse events.
Clinical translation challenges. Despite strong preclinical data, clinical trials of high-dose EPO for acute stroke and traumatic brain injury have been disappointing. The German Multicenter EPO Stroke Trial (2009) found no benefit and increased mortality in the EPO-treated group, possibly due to thromboembolic complications from increased red cell mass. This has driven research toward non-erythropoietic EPO derivatives, including carbamylated EPO (CEPO) and asialo-EPO, which retain tissue-protective activity without stimulating red blood cell production. These derivatives could, in theory, provide neuroprotection without the cardiovascular risks that limited high-dose EPO therapy. For related coverage of exercise-related peptide biology, see collagen for exercise-induced joint pain.
EPO Today: Biosimilars, HIF Stabilizers, and a Shifting Landscape
The EPO therapeutic landscape has shifted substantially since the early blockbuster era. Patent expirations have enabled biosimilar EPO products (including epoetin alfa biosimilars and epoetin zeta) that have reduced costs, particularly in dialysis centers and oncology practices. The global ESA market remains large but is no longer growing.
A new class of drugs, HIF-prolyl hydroxylase inhibitors (HIF-PHIs), has emerged as an alternative to injectable EPO for CKD anemia. Roxadustat, daprodustat, and vadadustat are oral drugs that stabilize HIF, mimicking the hypoxic signal that triggers endogenous EPO production. Roxadustat was approved in China (2018), Japan (2019), and the EU (2021) for CKD anemia, though FDA approval was delayed by cardiovascular safety concerns. These drugs stimulate EPO production from the patient's own kidneys and liver, potentially providing a more physiological approach to anemia correction than exogenous EPO injection.
The HIF-PHI development also raises new questions for anti-doping authorities. Unlike injected recombinant EPO, which can be detected by glycosylation analysis, HIF-PHI drugs stimulate production of the athlete's own endogenous EPO, making detection dependent on identifying the drug itself (a small molecule) or its metabolites rather than an abnormal EPO protein. WADA added HIF stabilizers to its prohibited list, and detection methods based on mass spectrometry of urine samples have been developed, but the field remains an active area of anti-doping research.
The parallel trajectories of EPO as medicine and EPO as doping agent continue to evolve together, each development in one domain creating consequences for the other. New therapeutic EPO variants designed for better patient outcomes inevitably raise new detection challenges. The 2019 Nobel Prize for the HIF pathway underscored that EPO biology remains a frontier of fundamental science, while the ongoing doping control arms race demonstrates that this same biology carries persistent ethical and regulatory implications that extend far beyond the laboratory.
The Bottom Line
Erythropoietin is a 165-amino-acid glycoprotein that controls red blood cell production and earned a Nobel Prize for the oxygen-sensing pathway that regulates it. Approved in 1989 for kidney disease anemia, EPO transformed nephrology before being co-opted as cycling's most notorious doping agent. Safety trials in the mid-2000s revealed cardiovascular risks at higher hemoglobin targets, leading to FDA black box warnings. Beyond hematopoiesis, EPO shows neuroprotective and cardioprotective properties through non-canonical receptors, though clinical translation of these effects remains challenging. The field continues to evolve through biosimilars, oral HIF stabilizers, and non-erythropoietic EPO derivatives designed to separate tissue protection from blood cell stimulation.